Meda expands the collaboration with Recordati

Meda expands the collaboration with Recordati, a European pharma company based in Italy, by signing a long-term agreement for marketing a new combination product in Spain – one of the largest European markets. The combination product consists of lercanidipine (calcium antagonist) and enalapril (an ACE inhibitor) – two well-known pharmaceutical substances. The product is indicated for the treatment of high blood pressure.

Meda already has marketing rights for this combination product in Germany and Scandinavia. The product launch has started in Germany and will be registered in Spain through the mutual recognition procedure.

---